One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment. (PubMed, Mult Scler Relat Disord) - Sep 24, 2026 - "Standardized rituximab achieved comparable MRI lesion suppression, but comparative clinical efficacy and serious-infection risk remain uncertain."
Journal • Retrospective data • Review • CNS Disorders • Infectious Disease • Multiple Sclerosis
|
|
Ahmed Shaheen; Anas Mansour; Baraah Abu Alsel; Enas Kamal Abdalaziz Seyed; Mostafa Meshref; Ram Saha; Safya E Esmaeel; Yehia Nabil
|